Quick Takeaways
- MORGAN STANLEY filed SCHEDULE 13G for C4 Therapeutics, Inc. Common Stock (CCCC).
- Disclosed ownership: 5.4%.
- Date of event: 31 Dec 2024.
MORGAN STANLEY - 31 Dec 2024 SCHEDULE 13G Report for C4 Therapeutics, Inc. Common Stock (CCCC)
- Filing Manager
- MORGAN STANLEY
- Reporting Manager
- Morgan Stanley
- Security
- C4 Therapeutics, Inc. Common Stock
- Symbol
- CCCC
- Shares outstanding
- 70,903,889 shares
- Disclosed Ownership
- 3,828,810 shares
- Ownership
- 5.4%
- Form type
- SCHEDULE 13G
- Filing time
- 03 Feb 2025, 13:59:29 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 07 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MORGAN STANLEY disclosed 5.4% ownership in C4 Therapeutics, Inc. Common Stock (CCCC) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 03 Feb 2025, 13:59.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | 5.4% | 3,828,810 | 0 | 3,828,148 | Christopher O'Hara | Authorized Signatory, Morgan Stanley |